Official Title
Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19
Brief Summary

Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon after exposure to varicella zoster virus, rabies, and hepatitis B virus. Neutralizing antibodies against MERS, SARS-CoV-1 and SARS-CoV-2 have been shown to be present in patients previously infected with MERS, SARS-CoV-1 and SARS-CoV-2 respectively. During the 2003 SARS outbreak in Hong-Kong,a non-randomized study in hospitalized SARS patients showed that treatment with convalescent plasma (convP) from SARS-recovered donors significantly increased the day 22 discharge rate and decreased mortality. A study in non-human primates showed that rhesus macaques could not be re-infected with SARS-CoV-2 after primary infection. With no proven effective therapy against COVID, this study will evaluate the safety and efficacy of convalescent plasma from COVID-recovered donors as a treatment for hospitalized patients with symptomatic COVID-19. The study will focus on patients who tested positive for SARS-CoV-2 in the last 96 hours before inclusion Primary objectives • Decrease overall mortality in patients within COVID disease Study design: This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP with standard of care. Patient population: Patients with PCR confirmed COVID disease, age >18 years Donors will be included with a known history of COVID who have been asymptomatic for at least 14 days. Intervention: 300mL of convP Duration of treatment: ConvP will be given as a one-time infusion Duration of follow up: For the primary endpoint: until discharge or death before day 60, whichever comes first. For the secondary endpoints (with separate consent) up to 1 year. Target number of patients: 426 Target number of donors: 100 Expected duration of accrural: 36 months

Detailed Description

Secondary (exploratory) objectives



- Evaluate the effect of 300ml convP on hospital stay



- Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 and 30



- Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 in the

subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80



- Evaluate the effect of 300ml convP on mortality in patients admitted to the ICU



- Evaluate the effect of 300ml plasma therapy on hospital days for patients admitted to

the ICU within 24 hours after admission



- Evaluate the impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways



- Evaluate the difference in effect of convP on mortality in patients with a duration of

symptoms < or > the median duration of symptoms in the study population



- Evaluate the impact of CTL and NK cell immunity on the likelihood of being protected

from immune serum transfer



- Safety of convP therapy



- Evaluate the impact of covP on long-term lung function

Active, not recruiting
COVID-19

Biological: Convalescent plasma
Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.
Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products
Convalescent plasma

Eligibility Criteria

Inclusion Criteria: - Patients with PCR confirmed COVID disease - Admitted to the hospital - The most recent PCR positive sample is 96 hours

Donors: Eligibility for plasma donation

Inclusions Criteria: - A history of COVID infection that was documented by PCR - Known ABO-Resus(D) blood group - A screening for irregular antibodies with a titer ≤ 1:32 - Asymptomatic for at least 14 days - Written informed consent regarding the plasmapheresis procedure - Tested negative for HIV, HBV, HCV, HEV, HTLV and syfilis

Exclusion Criteria: - Age 65 years - Weight

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
Netherlands

Bart Rijnders, MD, PhD
Principal Investigator
Erasmus Medical Center

Erasmus Medical Center
Sanquin Plasma Products BV
NCT Number